Peptide Association

Insights

NewsBlog
Start free intake

DisclosurePeptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.

All peptides

Cardiovascular · FDA Approved

Nesiritide (Natrecor)

FDA-approved

How to ask your doctor
Written by Peptide Association Editorial TeamLast reviewed Editorial policy

01 · Overview

A recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide produced by ventricular cardiomyocytes in response to volume overload and wall stress. Nesiritide binds natriuretic peptide receptor A (NPR-A), raising intracellular cGMP to produce vasodilation and natriuresis.

In hospitalized patients with decompensated heart failure it lowered pulmonary capillary wedge pressure more than nitroglycerin or placebo (PMID 11911755). The branded product, Natrecor, is now listed as discontinued in the US.

02 · Research summary & key findings

FDA-approved in 2001 for early relief of dyspnea in acute decompensated heart failure (PMID 21732835). The VMAC trial found improved hemodynamics and some self-reported symptoms compared with nitroglycerin or placebo (PMID 11911755). The large ASCEND-HF trial (7,141 patients) found only a small, non-significant effect on dyspnea, no change in 30-day death or rehospitalization, no worsening of renal function, and more hypotension, concluding that nesiritide could not be recommended for routine use (PMID 21732835).

03 · Regulatory status

Nesiritide (Natrecor) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Nesiritide (Natrecor) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.

04 · Administration routes

  • Intravenous

References

  1. [1]Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA, 2002. PMID 11911755
  2. [2]Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med, 2011. PMID 21732835

Primary literature

Related peptides in Cardiovascular

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.